The advantage of repurposing PI3K inhibitors for infectious disease treatment is they are already FDA approved for cancer therapy and there is abundance research into PI3K inhibitors (Garber, 2014; Zhang et al., 2020; Mishra et al., 2021; Vanhaesebroeck et al., 2021; Richardson et al., 2022). This evidence concerns the gene PIK3CD and infectious disease.